BCR/ABL 210 kD fusion protein 259-269 (HLA-A*03:01) (HLA-A*11:01)
( ATGFKQSSK )
This peptide has high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide composed BCR-ABL 210 kD fusion protein-derived peptide of ATGFKQSSK sequence covering 259-269 and A*03:01, A*11:01 molecule.
| Sequence: | ATGFKQSSK | |
| Gene: | BCR | |
| Delivery: | 3 weeks | |
| C-Terminus: | OH | |
| N-Terminus: | H | |
| Amount: | 1 mg | |
| Counter Ion: | TFA | |
| Protein: | Human Bcr-abl 210 kD fusion protein | |
| Species: | Human | |
| Allele: | HLA-A*03:01 HLA-A*11:01 | |
| Application : | Flow Cytometry | |
| Indication : | Cancer | |
| Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:
Special references for this product will come soon.
For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
€60.40*
Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Product number:
EP11088_1